bismuth potassium citrate + esomeprazole + amoxicillin + furazolidone

Bismuth potassium citrate + esomeprazole + amoxicillin + furazolidone is a bismuth-containing quadruple therapy (BQT) regimen used for the eradication of *Helicobacter pylori* infection. This specific combination has been extensively studied and developed by institutions such as **Huadong Hospital Affiliated to Fudan University** to address the rising challenge of antibiotic resistance, particularly to clarithromycin and metronidazole. The regimen employs a multi-mechanistic approach: **esomeprazole** is a proton pump inhibitor that reduces gastric acid secretion, thereby increasing the stability and efficacy of antibiotics in the stomach; **bismuth potassium citrate** provides direct bactericidal activity against H. pylori and offers mucosal protection; **amoxicillin** is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis; and **furazolidone** is a nitrofuran antibiotic that interferes with bacterial DNA and enzymatic processes. This quadruple therapy is often utilized as a first-line or rescue treatment in regions with high antibiotic resistance profiles.

Other names

BQT-EAFEsomeprazole-based bismuth quadruple therapyBismuth-containing quadruple therapy with esomeprazole, amoxicillin, and furazolidone